Back to top
more

AC Immune (ACIU)

(Real Time Quote from BATS)

$2.39 USD

2.39
65,207

+0.04 (1.70%)

Updated Apr 29, 2024 11:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ACIU

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

AC Immune [ACIU]

Reports for Purchase

Showing records 21 - 40 ( 62 total )

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 21

06/17/2022

Daily Note

Pages: 5

Tracers, Vaccines, and Non-AD Programs Might Have a Long-Term Growth Potential for AC Immune

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 22

04/29/2022

Company Report

Pages: 8

Considerations for Crenezumab’s Phase 2 Top-Line Data Readout in 1H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 23

03/30/2022

Daily Note

Pages: 5

AC Immune’s R&D Day Showcased the Strength of Non-AD Programs with Potential for Future Growth

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 24

03/23/2022

Company Report

Pages: 7

AC Immune’s Alpha-Synuclein Tracer--A Potential Breakthrough for Alpha Synucleopathies

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 25

03/18/2022

Industry Report

Pages: 7

Bird''s Eye View of Disease-Modifying Targets of Parkinson''s Disease-AD/PD 2022 Live from Barcelona

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 26

03/17/2022

Daily Note

Pages: 8

Do You Know About the Current State-of-the-Art AD/PD Biomarkers?

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 27

02/15/2022

Daily Note

Pages: 5

ACI-35.030 Gets It Right, Selectively Hits Pathological Tau in the Phase 1b/2a Interim Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 28

11/11/2021

Daily Note

Pages: 4

Modest Effect of Semorinemab Not Enough for Mild-to-Moderate AD Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 29

11/09/2021

Company Report

Pages: 7

Expectations from the Biomarker Data at CTAD 2021; Reit Buy and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 30

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ACIU

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 31

08/31/2021

Daily Note

Pages: 4

First Cognitive Results for Anti-Tau Monoclonal Antibody Semorinemab Pushes Tau to the Fore

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 32

08/05/2021

Company Report

Pages: 8

Progress Across Diversified Neurodegeneration-Focused Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 33

07/28/2021

Daily Note

Pages: 5

Addition of A Late-Stage PD01 Program Strengthens PD Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 34

05/18/2021

Company Report

Pages: 4

Expansion of Phase 1b/2a phospho-Tau Vaccine Might Catalyze the ACI-035.030 Program

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 35

04/29/2021

Company Report

Pages: 9

2021 Is All about Anti-Tau and Anti-Abeta Vaccines¯Our Thoughts

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 36

04/01/2021

Company Report

Pages: 7

Morphomer Platform AC Immune''s Chamber of Secrets Keep Pipeline Energized

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 37

03/24/2021

Company Report

Pages: 7

Diversified Portfolio and Multi-Prong Approach can Drive Growth in 2021; Reit Buy and Raising PT to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 38

03/17/2021

Company Report

Pages: 7

ACI-24-Key Takeaways from the Global Down Syndrome Symposium

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 39

02/11/2021

Daily Note

Pages: 5

We Believe in Tauism

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 40

11/17/2020

Company Report

Pages: 7

Beyond Semorinemab - Pipeline Implications

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party